Two different scientific papers, published in different contexts, point to the same uncomfortable truth: nicotine is more complex than the slogans suggest.

In a study on patients with Mild Cognitive Impairment, researchers administered 2 mg of nicotine gum and observed statistically significant improvements in working memory and positive mood compared to a control group. Although it was not a massive trial and it does not prove nicotine as a miracle drug, within controlled conditions, low-dose nicotine showed measurable cognitive effects.

Meanwhile, a review published in Frontiers in Aging Neuroscience examined nicotine’s role in cognitively normal older adults. The authors describe how nicotine interacts with the brain’s cholinergic system, the system deeply involved in attention and memory. Several studies reviewed suggest that nicotine can improve certain cognitive functions, especially in individuals starting from a lower baseline. But here’s the key detail: the benefit depends on dose.

The review highlights a critical point: an “inverted-U” relationship. Low or optimal doses may help. Higher doses may impair performance. So in this case, precision matters. The same principle holds in the MCI study, where a clearly defined 2mg dose was administered under controlled conditions.

Another indication that the conversation around nicotine is evolving comes from mainstream neuroscience discussions. Dr. Andrew Huberman, a neuroscientist at Stanford University, has discussed how nicotine affects the brain and its potential to enhance focus. He explains that nicotine interacts with acetylcholine receptors, which play a key role in attention and alertness, and can increase dopamine signaling associated with motivation and cognitive engagement.

In all cases, those researchers assume a fundamental premise: that nicotine can have positive effects, and must be available in small, measurable, and adjustable amounts.

You Cannot Talk About Low Doses Without Access

This is where the policy contradiction becomes impossible to ignore. 

If researchers are studying the potential effects of low-dose nicotine, only then will low-dose administration be possible. Outside a laboratory, adults don’t interact with nicotine in milligrams written on a study protocol. They use the products available to them. If those products don’t allow flexibility in nicotine strength or delivery, then meaningful dose control becomes difficult.

Cigarettes (in many markets the only widely and unrestrictedly available tool to consume nicotine in the market) do not allow for precision. Combustion delivers nicotine alongside thousands of toxic compounds, and the dosing is anything but controlled. If regulations remove or severely restrict products that allow nicotine strength selection and flexible intake, including open-system vapor devices, then real-world dose control becomes far more difficult.

At the same time, it’s contradictory to defend “low-dose research” in academic journals while supporting policies that eliminate the practical ability to choose low doses in everyday life.

Harm Reduction Requires Regulatory Coherence

This is not an argument that nicotine should be used by non-smokers as a brain booster. The evidence does not support that conclusion. Nicotine is addictive, and it carries risks.

But if the scientific conversation includes low-dose administration, then the policy conversation cannot ignore access. Administration of small amounts of nicotine is only realistic if adults who need to administer nicotine (for whatever reason, either to quit more effectively or even for a medical purpose) have access to regulated tools that allow dose adjustment and transparency. Otherwise, we are left with the contradiction that while research and science discuss precision, regulation eliminates the very mechanisms that enable it.

Research on nicotine continues to evolve, and more evidence about its potential mechanisms and possible benefits is discovered, then, governments are now facing an unavoidable reality. If specific low-dose therapeutic or cognitive applications are validated and can be administered openly and responsibly, regulatory frameworks will need to adapt. 

It would make little sense to recognize measured nicotine administration in clinical research while maintaining rigid policies that block adult access to regulated, dose-adjustable products.

Science is nuanced. Regulation should be too.